The goings - on with Admedus reminds me of the trials and tribulations Avita (AVH) went through over almost two decades before finally receiving FDA approval for its Recell. Although it had potentially a world class burns treatment, its progress was held up over the journey by questionable management, a revolving door of management personnel, shortage of money, recapitalisations and time consuming research and development requirements.
Despite all the headwinds AVH finally achieved its first goal of FDA approval recently.
Admedus is following a similar path with potentially a world class product, but needs people who know what they are doing and how to capitalise on what has been achieved so far.
Hopefully the new Board members and ownership will steer Admedus in the right direction.
- Forums
- ASX - By Stock
- AVR
- Trials And Tribulations
Trials And Tribulations
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$9.10 |
Change
-0.810(8.17%) |
Mkt cap ! $192.3M |
Open | High | Low | Value | Volume |
$9.50 | $9.77 | $9.01 | $212.2K | 22.63K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 298 | $9.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$9.85 | 1000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 298 | 9.010 |
1 | 1000 | 9.000 |
1 | 200 | 8.700 |
1 | 200 | 8.500 |
2 | 200 | 8.000 |
Price($) | Vol. | No. |
---|---|---|
9.850 | 1000 | 1 |
9.910 | 231 | 2 |
10.000 | 10250 | 2 |
10.200 | 545 | 1 |
10.500 | 10000 | 1 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online